Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial - Wikidata - wikimedia - TriplyDB

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

http://www.wikidata.org/entity/Q28286011

about

Screening for prostate cancer Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Early detection of prostate cancer: AUA Guideline.Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men Prostate-specific antigen screening in prostate cancer: perspectives on the evidence Prevention and early detection of prostate cancer.What do the screening trials really tell us and where do we go from here?Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.Optimization of PSA screening policies: a comparison of the patient and societal perspectives Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity?A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.Overdiagnosis of prostate cancer.The impact of PLCO control arm contamination on perceived PSA screening efficacy.Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening Active surveillance for prostate cancer Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)Biomarkers in prostate cancer surveillance and screening: past, present, and future.PSA screening for prostate cancer: why so much controversy?The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context.Risk-based prostate cancer screening: who and how?Implementation of PSA-based active surveillance in prostate cancer.Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum.Re: Determinants of participation in prostate cancer screening: A simple analytical framework to account for healthy-user bias.Prostate-specific antigen screening for prostate cancer in older men in the United States of America.Implications of the new AUA guidelines on prostate cancer detection in the U.S.Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.What explains the differences between centres in the European screening trial? A simulation study.Prostate cancer screening-when to start and how to screen?

P2860

Q24201690-E9ED2449-C747-4F96-9D7A-A80A223F813E Q26748873-3E83FE98-F9C0-49AD-900A-BE246357D8A4 Q26781093-ADC56544-09D4-4EA8-B2BA-42B327E336B8 Q28251617-9F5E23AA-585E-477F-9AC7-61943A7D17FA Q30239973-A5A1B1BE-2DE0-442E-B4B6-F2A0060E0866 Q33608474-64CABC31-1B27-46F3-8E0A-A487DD72402E Q34171025-DFA59519-781C-4736-A85E-5BD3ADCFA900 Q34354430-DE506577-2028-4FEC-870A-C18F61745781 Q34371057-A45EFF42-97DF-45E8-A945-7EDD55C3264A Q35234770-D7013FD5-1628-4C7F-BB25-4648F3DFE6EA Q35541638-7559C174-014A-463E-A265-E1EAB1BEE120 Q35677465-4EE88F7F-A278-4A6C-A4F5-7D21DB640CB1 Q35783202-CAE2658C-CD9C-4985-9DE7-E7F5915134FD Q36145417-C2E06484-2842-4452-B06E-C01839B4572D Q36179431-06A11D3B-2801-4F61-B052-A51C51254D2A Q36218380-65E0B1C2-C319-4435-9F42-B130C36CDB8F Q36493623-BAD28D99-4649-4AF2-8CD5-19C810F318B4 Q36520508-C1EB2E32-2FE2-4AD1-8D5D-21DDA42BF05A Q36567476-B43F7696-FDC2-4039-938E-42A164E761F0 Q36706929-B9112665-9A4C-4548-89CB-629E15F7871D Q37138594-315165B3-8C47-4364-9F63-B8B5EB94FB80 Q37155070-773BA8B4-0EFA-4B51-933A-29E7047D554D Q37300931-D2DDB49A-A656-414D-9E61-3B3FA563E632 Q37436987-1ADA469A-3DB7-4191-9E71-1E554060B673 Q37878463-876192AF-5255-4EE1-94A7-AEF9D322CB8F Q38093463-D256BAF2-E17B-49FA-A45C-2AB5582167EB Q38239830-3B1C5D01-1E80-425F-9F17-0BBE7C2BC29E Q40425465-CBC1F0CB-9FC6-456B-8C90-84F5BAEC8E0B Q41437748-22E1144A-ED3B-4A0F-83D4-FAB255CF6983 Q41849568-5C908C96-0C93-451F-8F77-31B27DC5BB2B Q43183512-E5191D32-7F29-4BB6-8490-F85904E65246 Q45168057-CB35CD41-5CE0-4355-AE51-E4803E288903 Q46619813-2CFA9D15-806C-48A1-9F8D-48D429F5F0CD Q47324732-C8429FCF-509C-4CE8-8BF5-873A8BC8FF42 Q47358352-FF8DA9D8-71B7-47FD-8587-CDAF47814AFD Q48047521-213D801B-BBF5-4620-988A-B8029BF7E5FD Q48327349-3F751F79-185D-4C90-AA22-A6300CDF9F21 Q51193176-E464BC2C-A188-4ADE-9829-601D23F0F28F Q51302170-B94655B9-07DA-4261-AAB4-B3891591958D Q52624230-8D614ED4-C327-4D6E-89B9-81C74D66249E

P2860

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

http://www.wikidata.org/entity/Q28286011

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@ast

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@en

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@nl

type

label

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@ast

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@en

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@nl

prefLabel

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@ast

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@en

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@nl

P1433

Q28286011-B1A26583-BC56-4E23-A179-FAF8789CD9B4

P1476

Q28286011-49352FF5-7710-4B17-8DDA-30EE61E80177

P2093

Q28286011-6C5823DE-7225-469E-B3C0-72D6C01163F7

Q28286011-74FC4B7B-38E9-4597-818B-A34D078235ED

Q28286011-757367C5-D831-4111-AFC7-71F181C1AAF7

Q28286011-B0D90F88-6D2D-42F5-A475-197A1C9D78AD

Q28286011-CD8F6388-FA28-49BB-988F-E9DFB3A6EE50

Q28286011-E0C11DB7-8848-4A5B-906D-D4CA6599F25A

P2860

Q28286011-2A4FFE7D-CE6D-42D6-98EC-FB85DADBABE0

Q28286011-4414EC92-ED28-4173-B6A3-856FF53D6384

Q28286011-AF858C0C-28DE-420B-BB77-3EED1DD72E4F

Q28286011-B0CE8F10-B1AD-468D-BFE9-D4B43C6FF382

Q28286011-C5B22B88-A32B-470B-ADA1-7E53F2521F51

Q28286011-CFB3C6C3-7C6A-497A-9996-276493782584

Q28286011-D475A6A9-72A0-43A9-8BEE-4BBC424C75AE

Q28286011-DDFFC286-4D5B-4EF7-BE51-6D4D1D2F9515

Q28286011-E3F13E4B-BB24-496B-B486-6356BE1C0D89

P304

Q28286011-942747CF-F6CF-45B1-BDB7-2AB15B082FB3

P31

Q28286011-20B41845-E0D1-4A98-A199-6BC73632C375

P3181

Q28286011-10FDC200-DAF3-4095-AA74-17A4069A3FDD

P356

Q28286011-3899DD08-8D61-4E54-A91A-F1A86F2C8C3E

P407

Q28286011-4F113C76-D394-4456-BAB7-BAB365B5966D

P433

Q28286011-210FEEB2-1217-47E6-8048-32F4C615BB85

P478

Q28286011-20B41C7B-F424-4B28-9400-6B7A0B3F9497

P577

Q28286011-F462DB14-7ED6-460D-814B-483523DB5619

P698

Q28286011-CDED50F9-FC33-4B2D-95EC-D4F51693B055

P3181

P356

1740774510374091

P1433

Clinical Trials

P1476

Assessing contamination and co ...... (PLCO) Cancer Screening Trial

@en

P2093

Amanda Blacka

http://www.w3.org/2001/XMLSchema#string

Anthony Miller

http://www.w3.org/2001/XMLSchema#string

Barnett S Kramer

http://www.w3.org/2001/XMLSchema#string

Christine Berg

http://www.w3.org/2001/XMLSchema#string

Paul F Pinsky

http://www.w3.org/2001/XMLSchema#string

Philip C Prorok

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

Screening and prostate-cancer mortality in a randomized European study

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Testing for prostate and colorectal cancer: comparison of self-report and medical record audit.

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.

Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute.

P304

303-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2367518

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1740774510374091

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20571134

http://www.w3.org/2001/XMLSchema#string